Bourgeon Capital Management LLC Trevena Inc Transaction History

Bourgeon Capital Management LLC

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 03, 2022	SELL	$0.41 - $0.63 $5,740 - $8,820	-14,000 Closed	0 $0
Q4 2021 Jan 31, 2022	SELL	$0.57 - $1.29 $3,419 - $7,740	-6,000 Reduced 30.0%	14,000 $8,000
Q3 2021 Nov 09, 2021	BUY	$1.11 - $1.7 $5,550 - $8,500	5,000 Added 33.33%	20,000 $25,000
Q2 2021 Jul 19, 2021	SELL	$1.46 - $2.25 $7,300 - $11,250	-5,000 Reduced 25.0%	15,000 $25,000
Q1 2021 May 13, 2021	BUY	$1.77 - $2.93 $35,400 - $58,600	20,000 New	20,000 $36,000

Q3 2020 Oct 28, 2020	SELL	$1.53 - $3.13 $22,950 - $46,950	-15,000 Closed	0 $0
Q2 2020 Jul 27, 2020	SELL	$0.48 - $1.75 $17,280 - $63,000	-36,000 Reduced 70.59%	15,000 $23,000
Q1 2020 May 07, 2020	BUY	$0.56 - $0.97 $5,600 - $9,700	10,000 Added 24.39%	51,000 $29,000
Q4 2019 Feb 04, 2020	BUY	$0.62 - $1.06 $7,440 - $12,720	12,000 Added 41.38%	41,000 $34,000
Q3 2019 Nov 04, 2019	SELL	$0.81 - $1.06 $16,200 - $21,200	-20,000 Closed	0 $0
Q2 2019 Jul 18, 2019	BUY	$0.94 - $1.6 $18,800 - $32,000	20,000 New	20,000 $21,000
Q4 2018 Jan 17, 2019	SELL	$0.39 - $3.47 $36,075 - $320,975	-92,500 Closed	0 $0
Q3 2018 Oct 25, 2018	BUY	$1.39 - $2.25 $18,070 - $29,250	13,000 Added 16.35%	92,500 $196,000
Q2 2018 Jul 19, 2018	BUY	$1.44 - $2.24 $14,400 - $22,400	10,000 Added 14.39%	79,500 $114,000
Q1 2018 Apr 27, 2018	SELL	$1.51 - $2.06 $103,133 - $140,698	-68,300 Reduced 49.56%	69,500 $114,000
Q4 2017 Feb 05, 2018	BUY	$1.4 - $2.6 $71,820 - $133,380	51,300 Added 59.31%	137,800 $220,000
Q3 2017 Oct 27, 2017	BUY	$2.22 - $2.79 $192,030 - $241,335	86,500	86,500 $221,000

Ticker TRVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 173,680,992
Market Cap $34.7M
Description
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV...

Get notified when there are updates to the investment portfolio of Bourgeon Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Bourgeon Capital Management LLC with notifications on news.